Arbutus Biopharma Corp (ABUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) has a cash flow conversion efficiency ratio of -0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.11 Million) by net assets ($260.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Arbutus Biopharma Corp market cap and net worth for the company's overall valuation and market capitalisation.
Arbutus Biopharma Corp - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Arbutus Biopharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arbutus Biopharma Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arbutus Biopharma Corp ranked by their cash flow conversion efficiency. Explore cash flow quality index of Arbutus Biopharma Corp to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Fortune Techgroup Co Ltd
SHE:300493
|
0.100x |
|
Nanjing Xinlian Electronics Co Ltd
SHE:002546
|
0.029x |
|
Beazer Homes USA Inc
NYSE:BZH
|
-0.239x |
|
China Motor Corp
TW:2204
|
0.028x |
|
SolGold Plc
F:S8F
|
0.128x |
|
Sipef NV
BR:SIP
|
0.138x |
|
Aeva Technologies, Inc. Common Stock
NYSE:AEVA
|
-0.447x |
|
Darma Henwa Tbk
JK:DEWA
|
0.061x |
Annual Cash Flow Conversion Efficiency for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual cash flow conversion efficiency of Arbutus Biopharma Corp from 1998 to 2025. View latest Arbutus Biopharma Corp stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $76.58 Million | $-39.64 Million | -0.518x | +22.28% |
| 2024-12-31 | $97.37 Million | $-64.85 Million | -0.666x | +17.83% |
| 2023-12-31 | $106.02 Million | $-85.94 Million | -0.811x | -213.75% |
| 2022-12-31 | $136.85 Million | $-35.36 Million | -0.258x | +35.18% |
| 2021-12-31 | $169.44 Million | $-67.53 Million | -0.399x | +21.00% |
| 2020-12-31 | $101.97 Million | $-51.44 Million | -0.504x | +48.32% |
| 2019-12-31 | $72.74 Million | $-71.01 Million | -0.976x | -187.85% |
| 2018-12-31 | $200.23 Million | $-67.90 Million | -0.339x | -27.34% |
| 2017-12-31 | $182.50 Million | $-48.60 Million | -0.266x | +6.61% |
| 2016-12-31 | $203.00 Million | $-57.88 Million | -0.285x | -185.06% |
| 2015-12-31 | $547.68 Million | $-54.78 Million | -0.100x | +29.13% |
| 2014-12-31 | $88.00 Million | $-12.42 Million | -0.141x | -23.99% |
| 2013-12-31 | $59.19 Million | $-6.74 Million | -0.114x | -114.00% |
| 2012-12-31 | $40.92 Million | $33.27 Million | 0.813x | +156.28% |
| 2011-12-31 | $5.21 Million | $-7.52 Million | -1.445x | -37.84% |
| 2010-12-31 | $10.73 Million | $-11.25 Million | -1.048x | -608.93% |
| 2009-12-31 | $35.44 Million | $-5.24 Million | -0.148x | +33.28% |
| 2008-12-31 | $38.29 Million | $-8.48 Million | -0.222x | -49.67% |
| 2007-12-31 | $18.37 Million | $-2.72 Million | -0.148x | +99.12% |
| 2006-12-31 | $155.53K | $-2.62 Million | -16.866x | -2240.30% |
| 2005-12-31 | $-18.49 Million | $-14.57 Million | 0.788x | -17.14% |
| 2004-12-31 | $-10.50 Million | $-9.98 Million | 0.951x | +253.00% |
| 2003-12-31 | $43.38 Million | $-26.96 Million | -0.622x | -55.24% |
| 2002-12-31 | $45.35 Million | $-18.16 Million | -0.400x | -146.08% |
| 2001-12-31 | $61.49 Million | $-10.00 Million | -0.163x | +41.51% |
| 2000-12-31 | $30.03 Million | $-8.35 Million | -0.278x | -9.37% |
| 1999-12-31 | $26.88 Million | $-6.84 Million | -0.254x | +52.39% |
| 1998-12-31 | $14.43 Million | $-7.71 Million | -0.534x | -- |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more